Microbial proteins as new-generation therapeutic agents
Microbial virulence proteins (MPs) have shown therapeutic potential in animal disease models and several are progressing to clinical trials.
MPs induce selective cancer cell cytotoxicity, degrade oncoproteins, and can be used in conjugate therapies.
MPs are being repurposed as antidiabetic agents, mast cell modulators, and treatments for sepsis, renal disorders, and coagulopathies, which demonstrates their versatility.
New insights into MP–host interactions reveal novel mechanisms for immune modulation, targeted cytotoxicity, and tumor microenvironment reprogramming.
Compared to traditional drugs, MPs offer advantages such as specificity, scalable production, strong bioactivity, and reduced immunogenicity through advanced protein engineering techniques.
As potential next-generation therapeutics, MPs are gaining clinical importance and expanding microbe-based biopharmaceutical platforms
